

CYP4A22 Antibody (N-term) Blocking Peptide
Synthetic peptide
Catalog # BP8785a**Specification**

CYP4A22 Antibody (N-term) Blocking Peptide - Product InformationPrimary Accession [Q5TCH4](#)**CYP4A22 Antibody (N-term) Blocking Peptide - Additional Information**

Gene ID 284541

Other Names

Cytochrome P450 4A22, CYP4A22, Fatty acid omega-hydroxylase, Lauric acid omega-hydroxylase, CYP4A22

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP8785a](/products/AP8785a) was selected from the N-term region of human CYP4A22. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CYP4A22 Antibody (N-term) Blocking Peptide - Protein Information

Name CYP4A22

Function

Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate and palmitate. Shows no activity towards arachidonic acid and prostaglandin A1. Lacks functional activity in the kidney and does not contribute to renal 20-hydroxyeicosatetraenoic acid (20-HETE) biosynthesis.

Cellular Location

Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein

CYP4A22 Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

CYP4A22 Antibody (N-term) Blocking Peptide - Images

CYP4A22 Antibody (N-term) Blocking Peptide - Background

CYP4A22 catalyzes the omega-and (omega-1)-hydroxylation of various fatty acids such as laurate and palmitate. It shows no activity towards arachidonic acid and prostaglandin A1. This protein lacks functional activity in the kidney and does not contribute to renal 20-hydroxyeicosatetraenoic acid (20-HETE) biosynthesis.

CYP4A22 Antibody (N-term) Blocking Peptide - References

Hiratsuka M., et.al., Mutat. Res. 599:98-104(2006).